ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1674

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth

Peter Izmirly1, Mala Masson2, Michael Marmor3, Noel Zahr4, Nathalie Costedoat-Chalumeau5 and Jill Buyon1, 1NYU Grossman School of Medicine, New York, NY, 2NYU Langone Medical Center- Division of Rheumatology, New York, NY, 3Stanford University, Stanford, CA, 4Pitié-Salpêtrière Hospital, Paris, France, 5Inserm DR Paris 5, Paris, France

Meeting: ACR Convergence 2022

Keywords: Drug toxicity, pregnancy

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Reproductive Issues in Rheumatic Disorders

Session Type: Abstract Session

Session Time: 10:30AM-11:30AM

Background/Purpose: The preventive approach to congenital heart block with hydroxychloroquine (HCQ) [PATCH] study supported the efficacy of HCQ to reduce the recurrence rate of cardiac disease. This study considered whether the drug had any effects upon the retinal development of these children, examined 5 years later.

Methods: Mothers in the PATCH study were treated with HCQ 400mg daily from 10 weeks of gestation and maintained throughout pregnancy. To assess maternal compliance, whole blood HCQ levels were measured using high performance liquid chromatography at baseline, second trimester, third trimester, delivery and cord blood. At age 5, ocular coherence tomography (OCT) was performed (CIRRUS HD-OCT,Carl Zeiss Meditec) on 10 HCQ children and 16 age, gender, racial/ethnically matched controls. Cross-sectional images were examined while blinded to exposure history, and retinal thickness values were recorded from the 9 Early Treatment Diabetic Retinopathy Study (ETDRS) regions. Standard deviations and Mann-Whitney analyses were obtained.

Results: The mean gestational age at birth of the mothers on HCQ was 37.5 compared to 37.7 in the controls. Cord and blood levels were quite variable between visits and subjects, ranging from 50-1349 ng/ml. OCT cross sections were of good quality in all cases and showed a completely normal appearance. The ETDRS thickness values showed typical normal variability within both control and treated groups, with no major outliers. The overall thickness averaged 295.7 µ in controls compared to 285.8 µ in HCQ cases. The treated eyes did not show any consistent regional loss of thickness and were slightly thinner in all 9 ETDRS regions. Statistical analysis was of limited value because of normal variability and the small sample, but no obvious discrepancies were noted.

Conclusion: The study data confirmed maternal adherence and the transplacental passage of HCQ. OCT anatomy was normal at 5 years of age in treated eyes. There is significant variation among ETDRS thickness values in normal adults, while no norms are established for children. Between small patient cohorts, a variation of 10 µ in average thickness would not be clinically significant. Thus, these OCT data show macular thickness to be slightly thinner in HCQ exposed children, but probably within clinical variation for normative samples and without any change in retinal morphology in OCT cross-sections. They provide reassurance that the use of HCQ In pregnancy does not cause obvious damage or developmental loss in the children of mothers given HCQ during pregnancy.


Disclosures: P. Izmirly, Momenta/Janssen; M. Masson, None; M. Marmor, None; N. Zahr, None; N. Costedoat-Chalumeau, UCB, Roche; J. Buyon, Equillium, GlaxoSmithKlein(GSK), L and M Healthcare Communications, Janssen, Boomcom, Merck/MSD.

To cite this abstract in AMA style:

Izmirly P, Masson M, Marmor M, Zahr N, Costedoat-Chalumeau N, Buyon J. In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/in-utero-exposure-to-hydroxychloroquine-does-not-associate-with-ocular-toxicity-as-assessed-by-optical-coherence-tomography-five-years-after-birth/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-utero-exposure-to-hydroxychloroquine-does-not-associate-with-ocular-toxicity-as-assessed-by-optical-coherence-tomography-five-years-after-birth/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology